NASDAQ:EPIX - ESSA Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.6348 +0.02 (+0.55 %)
(As of 02/17/2019 04:00 PM ET)
Previous Close$3.6348
Today's Range$3.5701 - $4.00
52-Week Range$1.87 - $5.83
Volume11,064 shs
Average Volume11,818 shs
Market Capitalization$22.94 million
P/E Ratio-1.43
Dividend YieldN/A
Beta2.61
ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Receive EPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPIX
CUSIPN/A
Phone778-331-0962

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.07 per share

Profitability

Net Income$-11,620,000.00

Miscellaneous

Employees15
Market Cap$22.94 million
OptionableNot Optionable

ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc (NASDAQ:EPIX) posted its quarterly earnings data on Thursday, December, 13th. The company reported ($0.39) EPS for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.04. View ESSA Pharma's Earnings History.

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for ESSA Pharma.

What price target have analysts set for EPIX?

1 Wall Street analysts have issued 1-year target prices for ESSA Pharma's shares. Their forecasts range from $0.70 to $0.70. On average, they expect ESSA Pharma's share price to reach $0.70 in the next year. This suggests that the stock has a possible downside of 80.7%. View Analyst Price Targets for ESSA Pharma.

What is the consensus analysts' recommendation for ESSA Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ESSA Pharma.

What are Wall Street analysts saying about ESSA Pharma stock?

Here are some recent quotes from research analysts about ESSA Pharma stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $14 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our current target is based 100% on the projected lead Aniten asset for prostate cancer. Factors that could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (2/15/2019)
  • 2. According to Zacks Investment Research, "ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. " (10/16/2018)

Has ESSA Pharma been receiving favorable news coverage?

News headlines about EPIX stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ESSA Pharma earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.

Who are some of ESSA Pharma's key competitors?

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the folowing people:
  • Dr. David Ross Parkinson, Pres, CEO & Director (Age 69)
  • Mr. David S. Wood, Chief Financial Officer (Age 62)
  • Mr. Peter A. Virsik, Exec. VP & COO (Age 48)
  • Dr. Raymond Andersen, CTO, Sec. & Director (Age 72)
  • Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 58)

How do I buy shares of ESSA Pharma?

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $3.6348.

How big of a company is ESSA Pharma?

ESSA Pharma has a market capitalization of $22.94 million. The company earns $-11,620,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. ESSA Pharma employs 15 workers across the globe.

What is ESSA Pharma's official website?

The official website for ESSA Pharma is http://www.essapharma.com.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962.


MarketBeat Community Rating for ESSA Pharma (NASDAQ EPIX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe EPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Featured Article: What is a Futures Contract?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel